| Bioactivity | Batifiban TFA, a cyclic peptide, is an antagonist of platelet glycoprotein GPⅡb/Ⅲa and inhibits platelet aggregation. Batifiban blocks the binding of circulating vitronectin to integrin ανβ3[1]. | ||||||
| Target | Glycoprotein GPⅡb/Ⅲa | ||||||
| Name | Batifiban TFA | ||||||
| Sequence | {Mpa}-Arg-Gly-Asp-Trp-Pro-Cys-NH2 (Disulfide bridge: Mpa1-Cys7) | ||||||
| Shortening | {Mpa}-RGDWPC-NH2 (Disulfide bridge: Mpa1-Cys7) | ||||||
| Formula | C34H47N11O9S2.xC2HF3O2 | ||||||
| Molar Mass | 817.94 (free base) | ||||||
| Appearance | 固体 | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture and light
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
||||||
| Reference | [1]. Chen H, et al. Safety, pharmacokinetic and pharmacodynamic studies of batifiban injection following single- and multiple-dose administration to healthy Chinese subjects. J Huazhong Univ Sci Technolog Med Sci. 2009 Feb;29(1):12-8. |
Batifiban TFA
CAS: F: C34H47N11O9S2.xC2HF3O2 W: 817.94 (free base)
Batifiban TFA, a cyclic peptide, is an antagonist of platelet glycoprotein GPⅡb/Ⅲa and inhibits platelet aggregation.
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.